The Perelman School of Medicine announces human trials for a novel gene-editing vector targeting ALS.
The Perelman School of Medicine has received conditional FDA clearance to begin Phase I trials of a new CRISPR-Cas13 vector targeting the SOD1 mutation implicated in familial ALS. Early animal studies showed a 41% reduction in motor neuron degeneration.
"The Perelman School of Medicine announces human trials for a novel gene-editing vector targeting ALS."
Life SciencesA BrainGate consortium trial reports the first sustained two-year recovery in a tetraplegic patient.
ClimateA new model published in Nature compresses the timeline by nearly a decade.
BusinessWharton's quarterly index documents the largest single-year reallocation in modern asset management.
PhysicsThe PPPL stellarator records sustained positive Q for 41 seconds.
Wharton's quarterly index documents the largest single-year reallocation in modern asset management.